Adobe Stock
Biocon has hit the fundraising trail. On Monday (June 16, 2025), the company opened a Qualified Institutional Placement (QIP), looking to raise Rs 4,500 crore by issuing fresh equity at a floor price of Rs 340.20 per share.
Why raise funds now?
This QIP is not a growth-hungry move, it’s a clean-up act. Biocon wants to use the proceeds to repay debt, especially at its subsidiary Biocon Biologics, which took on borrowings to buy Viatris’s biosimilar business.
Debt levels had become uncomfortable. The move is expected to ease interest costs and improve the company’s leverage.
But there’s a catch: More shares mean lower earnings per share (EPS) in the near term. And that’s got investors watching closely.
What Biocon does
Biocon is one of India’s biggest biotech firms. It makes generic active pharmaceutical ingredients (APIs), biosimilars (copycat biologic drugs), and also runs a contract research business through Syngene. Its drugs cater to diseases like diabetes, cancer and autoimmune conditions, and it sells to both regulated markets like the US and emerging ones.
Here’s a quick snapshot of where Biocon stands financially (as per Value Research data):
| Metric | Value |
|---|---|
| Market cap | Rs 42,675 crore |
| ROE | 7 per cent |
| ROCE | 7 per cent |
| P/E ratio | 42.1 |
| P/B ratio | 2 |
| EPS | Rs 8.2 |
| Book value/share | Rs 180.3 |
| Dividend yield | 0.1 per cent |
Value Research Online ratings
- Overall: 2/5
- Quality: 2/10
- Growth: 8/10
- Valuation: 5/10
- Momentum: 5/10
The bottom line
Biocon’s fundraising isn’t just about bringing in more cash, it’s about buying itself breathing room. For long-term investors, this could be a positive reset. But until that debt reduction translates into better earnings and improved capital efficiency, the stock may stay range-bound.
Serious about wealth? So are we.
Join thousands of smart investors who rely on Value Research Stock Advisor for expert-picked stocks, time-tested strategies and long-term discipline.
Stop guessing. Start growing. Check it out now: Value Research Stock Advisor.
Disclaimer: This is not a stock recommendation. This story was created with the assistance of artificial intelligence and is intended for informational purposes only. Please take it with a pinch of salt and do your own research or consult a financial advisor before making investment decisions.
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
